ReNeuron

THE CUSTOMISABLE EXOSOME DELIVERY PLATFORM OPTIMISED FOR SPECIFIC DRUG DELIVERY NEEDS

International Society of Cell & Gene Therapy May 2022

CFO Catherine Isted



DISCLAIMER

This Presentation is being supplied to you solely for your information and may not be reproduced, further distributed to any other person or published, in whole or in part, for any purpose. Subject to certain exceptions, this Presentation is not for distribution in the United States, Australia, Canada or Japan or any other jurisdiction where its distribution may constitute a violation of the laws of such jurisdiction.

The information contained in this document ("Presentation") has been prepared by ReNeuron Group plc (the "Company") and neither this Presentation, nor the information contained in it should be considered a recommendation by the Company or any of its shareholders, directors, officers, agents, employees or advisers in relation to any purchase of the Company's securities, including any purchase of or subscription for any shares (or securities convertible into shares) in the capital of the Company. This Presentation has not been fully verified and is subject to material updating, revision and further amendment. Any person who receives this Presentation should not rely or act upon it. This Presentation should not be re-distributed, re-published, reproduced or disclosed by recipients, in whole or in part.

While the information contained herein has been prepared in good faith, neither the Company nor any of its shareholders, directors, officers, agents, employees or advisers give, have given or have authority to give, any representations or warranties (express or implied) as to, or in relation to, the accuracy, reliability or completeness of the information in this Presentation, or any revision thereof, or of any other written or oral information made or to be made available to any interested party or its advisers (all such information being referred to as "Information") and liability therefor is expressly disclaimed. Accordingly, neither the Company nor any of its shareholders, directors, officers, agents, employees or advisers take any responsibility for, or will accept any liability whether direct or indirect, express or implied, contractual, tortious, statutory or otherwise, in respect of, the accuracy or completeness of the Information or for any of the opinions contained herein or for any errors, omissions or misstatements or for any loss, howsoever arising, from the use of this Presentation.

This Presentation may contain forward-looking statements that involve substantial risks and uncertainties, and actual results and developments may differ materially from those expressed or implied by these statements and past performance is no guarantee of future performance. These forward-looking statements are statements regarding the Company's intentions, beliefs or current expectations concerning, among other things, the Company's results of operations, financial condition, prospects, revenue generation, growth, strategies and the industry in which the Company operates. By their nature, forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. These forward-looking statements speak only as of the date of this Presentation and the Company does not undertake any obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date of this Presentation.

This Presentation has not been approved by an authorised person in accordance with Section 21 of the Financial Services and Markets Act 2000.

In no circumstances will the Company be responsible for any costs, losses or expenses incurred in connection with any appraisal or investigation of the Company. In furnishing this Presentation, the Company does not undertake or agree to any obligation to provide the recipient with access to any additional information or to update this Presentation or to correct any inaccuracies in, or omissions from, this Presentation which may become apparent. This Presentation does not constitute an offer or invitation to subscribe for or purchase any securities and neither this Presentation nor anything contained herein shall form the basis of any contract or commitment whatsoever. In particular, this Presentation is for information purposes and does not constitute an offer or invitation to subscribe for or purchase any securities in the United States. The securities of the Company have not been and will not be registered under the US Securities Act of 1933, as amended (the "US Securities Act") or the securities laws of any state or other jurisdiction of the United States and may not be offered, sold, resold, pledged, delivered, distributed or transferred, directly or indirectly, into or in the United States except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the US Securities Act and in accordance with any applicable state securities laws. There will be no public offering of the securities of the Company in the United States.

By participating in and/or accepting delivery of this Presentation you agree to be bound by the foregoing restrictions and the other terms of this disclaimer.

ReNeuron

RENEURON: A LEADER IN STEM CELL BASED EXOSOME TECHNOLOGIES

OUR SCIENCE: Exosome delivery platform with a range of <u>seven</u> proprietary cell lines that can be <u>optimised</u> for a particular payload and target

A

OUR PEOPLE: Highly skilled and passionate Team of 35 professionals with deep knowledge across Exosomes and iPSC research, CMC and regulatory with proven track record working with MHRA and FDA

- Alist

OUR FACILITIES: Research laboratories and offices based in Pencoed, Wales, with space to expand into GMP manufacturing within existing building



OUR KNOWHOW: CSO/Head of research >30 yrs experience in exosomes with extensive knowledge of EV Biology. CMC team - experts in process/analytical development, manufacturing and technology transfer.



WHY EXOSOMES?

A customisable, targeted delivery platform for complex drug modalities

- Proven ability to carry and deliver a variety of cargos including proteins and nucleic acids
- Can be genetically engineered to target specific tissues or cells
- Potential to deliver more than 1 bio-active cargo simultaneously
- Biological nanoparticles for intercellular communication Evades immune detection

Specific to ReNeuron

- Seven proprietary conditionally immortalised exosome producer stem cell lines
- Our catalogue of proprietary cells from neural and non neural tissue differentiates us from many others in the field, we believe leading to a greater chance for success
- Years of experience and knowledge in the manufacture of consistent cell banks to GMP 2 IND's
- Early preclinical animal data with our modified cortex-derived exosomes delivering BDNF demonstrates greater efficacy compared to recombinant protein alone when targeting specific regions of the brain when administered intrathecally



RENEURON'S USP: THE PORTFOLIO ADVANTAGE

THE CUSTOMISABLE EXOSOME DELIVERY PLATFORM, OPTIMISED FOR SPECIFIC DRUG DELIVERY NEEDS



Competitors – Single cell line approach

- Single cell line, single outcome
- 'One size fits all'

ReNeuron – Portfolio of Exosomes

- Exosomes have functional properties based on parent cell
- ReNeuron's seven conditionally immortalised cell • lines allows exosomes to be customised and optimised for a specific payload and targets

Producer cell line <u>optimised</u> for:

- Engineering efficiency
- Tissue targeting (on and off-target effects)
- Delivery (cytoplasm / nuclear)



Ability to produce Native, Passively-loaded and Engineered Exosomes

Providing an expanded range of Exosome products

DELIVERY OF THERAPEUTIC PROTEINS WITH RENEURON'S EXOSOMES

*In a preclinical setting

We believe this is the first time that a potentially therapeutic protein payload has been delivered to a specific site in the brain using Exosomes*

- Delivered by Intrathecal injection (lumbar puncture)
- Response observed only with Exosomes loaded with therapeutic protein
- This area of the brain (the striatum) is affected in Parkinson's and Huntington's disease
- In vivo functional studies are ongoing

Our goals: Building a fully validated and sustainable proprietary 'drug delivery platform business' through meaningful scientific and commercial partnerships

- **Build** a best in class end-to-end proprietary delivery technology and manufacturing platform
- **Progress** our 7 current partner programmes and **expand** with new named partners building a growing revenue stream
- **Undertake** further experiments the proving the strength and versatility of our platform
- **Develop** our proprietary programmes focused on delivery of therapeutic proteins to the brain via ReNeuron's neural exosomes
- **Continue to strengthen** our IP position in Exosomes currently 3rd largest globally
- Further develop our **Induced Pluripotent Stem Cell** (iPSC) Platform and out-license our legacy stem cell assets

SUMMARY

- Customisable Exosome delivery platform optimised for specific delivery needs
- Seven proprietary, conditionally immortalized exosome producer cell lines for production of discrete exosome populations
- Highly skilled and knowledgeable team
- Know-how and experience across research, CMC and regulatory to facilitate partners with their payload delivery requirements
- > Engineering capabilities to **target** specific cells or tissues
- Proven ability to load various cargos including RNA and proteins with evidence of the targeted and functional delivery of a protein *in vivo*
- > Further potential: iPSC platform, outlicensing stem cell assets

A leader in Stem Cell based Exosomes Technologies

ReNeuron

Pencoed Business Park | Pencoed Bridgend | CF35 5HY | UK T +44 (0) 203 819 8400 |E info@reneuron.com www.reneuron.com Ticker: RENE.L

Appendix

MEET THE RENEURON TEAM

lain Ross Chairman & Interim CEO

- Highly experienced board director with over 40 years experience in the international life sciences and technology sectors
- Senior commercial roles at Sandoz, Fisons and Roche
- Former Chairman, CEO, Director roles at Celltech, Quadrant and Redx Pharma
- Current Non-Exec Chairman at Silence Therapeutics
 ReNeuron

Catherine Isted ACMA Chief Financial Officer

- c.25 years experience in the healthcare and healthcare banking industry
- Formally part of the Financial Leadership team at Oxford Biomedica and instrumental in three capital raises totalling over £110m
- 19 years in healthcare in the city at Morgan Stanley, Nomura and Peel Hunt
- BSc in Chemistry and Chartered Accountant

Dr Randolph Corteling Head of Research

- 24 years' experience in medical research and drug discovery, spanning academia, biotechnology and the pharmaceutical industry
- Re-joined ReNeuron in Q1 2022 from Evox
- In 2007 joined ReNeuron where he established the first Exosomes programmes
- PhD in Medical and Surgical Sciences

Suzanne Hancock Head of Operations

- Suzanne joined ReNeuron in 2017 from GE Healthcare, where she spent c.12 years
 - She has held a number of managerial roles leading global cross functional teams engaged in the development and delivery of new products in the Life Sciences and Cell Therapy Industry
- BSc in Applied
 Biological Sciences

Prof. Stefano Pluchino Chief Scientific Officer

- Appointed CSO in May 2021
- He is Reader in Regenerative Neuroimmunology and Honorary Consultant at the University of Cambridge
- Stefano is internationally recognised as a leader and pioneer in the field of regenerative neuroimmunology and Exosomes

Shaun Stapleton Head of Regulatory Affairs and Pharmacovigilance

- Joined ReNeuron in 2015 from Voisin Consulting Life Sciences where he was a Director and Vice President of Regulatory Science.
- Prior regulatory affairs positions at Eli Lilly and Boehringer Ingelheim, beginning his career in research with Imperial Cancer Research Fund
- BSc in Biochemistry

CORPORATE AND MARKET INFORMATION

Company Facts

- Listed on AIM (RENE)
- Cash position (30 Sept 21): £17.4m
- Cash runway guidance: End Q2 2023
- At 4th May 2022
 - Share price: 38p
 - Market Capitalisation: £22 million (\$28 million)

Major Shareholders holding over 3% of the Company's ordinary shares*

Number of ordinary shares	% of issued share capital
Richard Griffiths and Controlled Undertakings	11.48%
Obotritia Capital KGaA	7.84%
Octopus Investments Nominees Ltd	5.89%
Rosetta Capital VI GP LP, on behalf of Rosetta Capital VI, LP	5.65%
Arthurian Life Sciences SPV GP Ltd, as GP of The Wales Life Sciences Investment Fund LP	5.27%

INDUCED PLURIPOTENT STEM CELL (ISPC) PLATFORM

- ReNeuron's induced pluripotent stem cell (iPSC) platform technology can reprogramme proprietary neural stem cells into a pluripotent state able to differentiate into any other form of cell
- iPSCs retain the immortalisation characteristic of the stem cells from which they are derived, resulting in highly stable cell lines
- Technology has the potential to lead to off the shelf therapeutics
- Also has the potential to produce exosomes with tissue-specific targeting ability
- Collaborations with University College London investigating potential use of CTX-iPSC cell lines to generate CAR-T / CAR-NK cells and separately the ability to differentiate into Schwann cells for potential use in peripheral nerve damage repair.

FOSUN复星

ReNeuron

O Collaboration with Fosun Pharma

- CTX Programme for stroke disability and hRPC programme in retinitis pigmentosa out-licensed in China to Fosun Pharma
- Deal terms secured of up to £80m in milestones

OUT-LICENSING OF STEM CELL PROGRAMMES

- Tiered royalties of 12-14%
- Discussions with Fosun on supplemental terms of the Technology Transfer agreement for CTX ongoing

O Next Steps

- To continue to progress the CTX and hRPC programmes with Fosun in China
- To complete ongoing Technology Transfer agreement with Fosun
- Out-license the CTX and hRPC programme in other geographies